Abstract
The c-Myc protein is diversely involved in normal cellular function, and its deregulation has been implicated in several cancers. Therefore, c-Myc is a validated target for anti-cancer therapeutics. Here, we developed a monoclonal antibody specific to an epitope involved in the protein–protein interaction and DNA binding of c-Myc. We selected two candidate epitopes based on the antigenicity prediction and 3-D structure of c-Myc and successfully obtained a c-Myc-specific monoclonal IgG2a antibody clone. Based on the immunoprecipitation assay, the antibody recognized overexpressed c-Myc as well as endogenously expressed c-Myc in cell lines. The antibody co-immunoprecipitated Max showing that the antibody can recognize the c-Myc-Max heterodimer in solution. The results from the ELISA-based DNA binding assay revealed that treatment with the monoclonal antibody inhibits the binding activity of c-Myc. Therefore, we suggest that our anti-c-Myc monoclonal antibody can be used as a starting material for the development of an anti-cancer drug targeting c-Myc.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Avignolo C, Bagnasco L, Biasotti B et al (2008) Internalization via Antennapedia protein transduction domain of an scFv antibody toward c-Myc protein. FASEB J 22(4):1237–1245
Berg T (2011) Small-molecule modulators of c-Myc/Max and Max/Max interactions. Curr Top Microbiol Immunol 348:139–149
Blackwood EM, Eisenman RN (1991) Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 251(4998):1211–1217
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM (1984) Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 224(4653):1121–1124
Conacci-Sorrell M, McFerrin L, Eisenman RN (2014) An overview of MYC and its interactome. Cold Spring Harb Perspect Med 4(1):a014357
Dang CV (1999) c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol 19(1):1–11
Dang CV (2012) MYC on the path to cancer. Cell 149(1):22–35
Guillard S, Minter RR, Jackson RH (2015) Engineering therapeutic proteins for cell entry: the natural approach. Trends Biotechnol 33(3):163–171
Hönnemann J, Sanz-Moreno A, Wolf E, Eilers M, Elsässer HP (2012) Miz1 is a critical repressor of cdkn1a during skin tumorigenesis. PLoS ONE 7(4):e34885
Hsieh AL, Walton ZE, Altman BJ, Stine ZE, Dang CV (2015) MYC and metabolism on the path to cancer. Semin Cell Dev Biol 43:11–21
Kiessling A, Sperl B, Hollis A, Eick D, Berg T (2006) Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules. Chem Biol 13(7):745–751
Kim D, Kwon S, Rhee JW et al (2011) Production of antibodies with peptide-CpG-DNA-liposome complex without carriers. BMC Immunol 12:29
Kwon S, Choi KC, Kim YE et al (2014) Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res 74(14):3844–3856
Marschall AL, Zhang C, Frenzel A et al (2014) Delivery of antibodies to the cytosol: debunking the myths. MAbs 6(4):943–956
Nair SK, Burley SK (2003) X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell 112(2):193–205
Oster SK, Ho CS, Soucie EL, Penn LZ (2002) The myc oncogene: marvelously complex. Adv Cancer Res 84:81–154
Park BK, Choi SH, Kim YE et al (2015) Monoclonal antibodies against the human respiratory syncytial virus obtained by immunization with epitope peptides and CpG-DNA-liposome complex. Monoclon Antib Immunodiagn Immunother 34(2):101–109
Park BK, Lee SI, Lee Y et al (2016) Effect of a monoclonal antibody against relaxin-2 on cancer cell growth inhibition. Appl Biol Chem 59(5):739–746
Posternak V, Cole MD (2016) Strategically targeting MYC in cancer. F1000Res. https://doi.org/10.12688/f1000research.7879.1.eCollection2016
Prochownik EV, Vogt PK (2010) Therapeutic targeting of Myc. Genes Cancer 1(6):650–659
Sakamuro D, Prendergast GC (1999) New Myc-interacting proteins: a second Myc network emerges. Oncogene 18(19):2942–2954
Scott AM, Wolchok JD, Old LJ (2012) Antibody therapy of cancer. Nat Rev Cancer 12(4):278–287
Sheiness D, Bishop JM (1979) DNA and RNA from uninfected vertebrate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J Virol 31(2):514–521
Sohn WJ, Kim D, Lee KW et al (2007) Novel transcriptional regulation of the schlafen-2 gene in macrophages in response to TLR-triggered stimulation. Mol Immunol 44(13):3273–3282
Soucek L, Jucker R, Panacchia L et al (2002) Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res 62(12):3507–3510
Stellas D, Szabolcs M, Koul S et al (2014) Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst 106(12). https://doi.org/10.1093/jnci/dju320
Varmus HE (1984) The molecular genetics of cellular oncogenes. Annu Rev Genet 18:553–612
Vogt PK (2012) Retroviral oncogenes: a historical primer. Nat Rev Cancer 12(9):639–648
Wang H, Hammoudeh DI, Follis AV et al (2007) Improved low molecular weight Myc-Max inhibitors. Mol Cancer Ther 6(9):2399–2408
Wang J, Ma X, Jones HM et al (2014) Evaluation of the antitumor effects of c-Myc-Max heterodimerization inhibitor 100258-F4 in ovarian cancer cells. J Transl Med 12:226
Wiese KE, Walz S, von Eyss B et al (2013) The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med 3(12):a014290
Yokoyama WM, Christensen M, Santos GD, Miller D (2006) Production of monoclonal antibodies. Curr Protoc Immunol. https://doi.org/10.1002/0471142735.im0205s74
Zhang W, Kater AP, Widhopf GF 2nd et al (2010) B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA 107(44):18956–18960
Acknowledgements
This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning in the Republic of Korea (NRF-2015R1A2A2A01007209, 2014M3C1A3051473, 2016M3A9B6916708, 2009-0093812). Byoung Kwon Park was supported by the Hallym University Postdoctoral Fellowship Program of 2017 (HLM-PF-2017-0001).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Byoung Kwon Park, Avishekh Gautam, Sony Maharjan, Su In Lee, Younghee Lee and Hyung-Joo Kwon confirm that this article content has no conflicts of interest.
Research Involving Human and Animal Rights
All institutional and national guidelines for the care and use of laboratory animals were followed. All procedures performed in studies involving animals were approved by the institutional animal ethical committee. This article does not include any studies using human subjects.
Informed Consent
The article does not contain any studies in patients by any of the authors.
Rights and permissions
About this article
Cite this article
Park, B.K., Gautam, A., Maharjan, S. et al. Production of Anti-c-Myc Monoclonal Antibody Inhibiting DNA Binding of c-Myc and Max Dimer by Epitope Peptide–CpG-DNA–Liposome Complex Without Carriers. Int J Pept Res Ther 25, 75–82 (2019). https://doi.org/10.1007/s10989-017-9649-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-017-9649-6